Coastline Trust Co Buys 10,492 Shares of AbbVie Inc. $ABBV

Coastline Trust Co boosted its stake in AbbVie Inc. (NYSE:ABBV) by 27.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,354 shares of the company’s stock after purchasing an additional 10,492 shares during the quarter. AbbVie makes up 1.1% of Coastline Trust Co’s investment portfolio, making the stock its 24th largest position. Coastline Trust Co’s holdings in AbbVie were worth $11,277,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of ABBV. Diversified Trust Co raised its position in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after buying an additional 10,891 shares in the last quarter. Permanent Capital Management LP bought a new position in shares of AbbVie in the third quarter worth approximately $720,000. Railway Pension Investments Ltd raised its stake in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after purchasing an additional 211,800 shares in the last quarter. World Investment Advisors raised its position in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after buying an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co grew its position in AbbVie by 93.4% in the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after acquiring an additional 15,502 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABBV has been the topic of several recent research reports. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Citigroup reduced their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Barclays assumed coverage on AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price for the company. Finally, UBS Group reduced their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Performance

Shares of ABBV stock opened at $206.32 on Friday. The firm has a market cap of $364.80 billion, a P/E ratio of 87.42, a P/E/G ratio of 0.72 and a beta of 0.34. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The business’s 50 day moving average price is $223.41 and its 200-day moving average price is $224.71.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the previous year, the firm earned $2.16 earnings per share. The business’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by corporate insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) released new global consumer research and updated educational programs that could support its aesthetics franchise and long‑term revenue diversification. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: Independent valuation and market‑commentary pieces highlight a recent share‑price pullback and renewed debate over AbbVie’s near‑term multiple; these analyses may lead to more analyst revisions but are not a direct operational hit. Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
• Negative Sentiment: FDA approved J&J’s Icotyde, the first oral IL‑23 inhibitor, creating direct competition for Skyrizi; analysts and articles warn Icotyde could capture significant market share because of oral dosing convenience, pressuring AbbVie’s key growth driver. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: multiple outlets report a ~5% intraday drop and continued underperformance vs. peers as investors price in Icotyde competition and reassess AbbVie’s growth outlook. Elevated volume suggests defensive positioning. ABBV Stock Slides 5%: Is J&J’s Icotyde a Threat to Skyrizi?
• Negative Sentiment: Breckenridge launched a generic version of Savella (milnacipran), which introduces additional generic competition in a product AbbVie previously marketed—incremental revenue headwind for that niche pain product. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.